We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice for medical professionals to use when assessing drivers with cardiovascular disorders.
Caution is required if prescribing febuxostat in patients with pre-existing major cardiovascular disease, particularly, in those with evidence of high urate crystal and tophi burden or those initiating urate-lowering therapy.
A professional resource on improving the detection and treatment of the high-risk conditions atrial fibrillation, high blood pressure and high cholesterol
Evidence and guidance to help healthcare professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health.
Projects granted during 2016 that have a primary purpose of translational applied research - human cardiovascular disorders.
Projects granted during 2014 that have a primary purpose of basic research into the cardiovascular, blood and lymphatic system.
Projects granted during 2015 that have a primary purpose of basic research: cardiovascular, blood and lymphatic system.
This publication brings together Public Health England's (PHE’s) broad-ranging work in addressing cardiovascular disease.
UKAP categorisation of exposure prone procedures (EPPs) carried out in vascular surgery, by risk of bleed-back and blood-borne virus transmission.
Systematic reviews and meta-analyses of randomised controlled trials have highlighted a dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors treated with omega-3-acid ethyl ester medicines compared to placebo.
An advisory panel working together with the DVLA providing expert advice with the aim of improving road safety.
Projects granted during 2015 that have a primary purpose of translational and applied research: cardiovascular disorders.
Projects granted during 2014 that have a primary purpose of translational and applied research: cardiovascular disorders.
Following a review, the MHRA has updated previous guidance (DSI/2022/003) on the use of paclitaxel coated devices (PCD) in the treatment of peripheral arterial disease (PAD).
Report by the Committee on the Medical Effects of Air Pollutants describing how long-term exposure to ambient air pollution can lead to cardiovascular disease.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.